MTOR and small cell lung carcinoma: To ensure that our findings on the activation of the RSK3-TSC2-mTOR-p70S6K1-BAD cascade by BETi are not restricted to 1 molecular subtype of SCLC, we treated LX95 cells with JQ1 for 1 week.